User profiles for Thomas Witzig

Thomas Witzig, MD

Professor of Medicine, Mayo Clinic
Verified email at mayo.edu
Cited by 80427

Targeting apoptosis pathways in cancer therapy

IM Ghobrial, TE Witzig, AA Adjei - CA: a cancer journal for …, 2005 - Wiley Online Library
Apoptosis, or programmed cell death, is a mechanism by which cells undergo death to
control cell proliferation or in response to DNA damage. The understanding of apoptosis has …

Rituximab for IgG4-related disease: a prospective, open-label trial

…, MD Topazian, A Khosroshahi, TE Witzig… - Annals of the …, 2015 - ard.bmj.com
Objectives To evaluate the efficacy of rituximab (RTX) in IgG4-related disease (IgG4-RD) in
an open-label pilot trial. Methods We treated 30 IgG4-RD patients with two doses of RTX (…

POEMS syndrome: definitions and long-term outcome: Presented in abstract form at the 41st annual meeting of the American Society of Hematology, New Orleans, LA …

…, DR Larson, PR Greipp, TE Witzig… - Blood, The Journal …, 2003 - ashpublications.org
The POEMS syndrome (coined to refer to polyneuropathy, organomegaly, endocrinopathy,
M protein, and skin changes) remains poorly understood. Ambiguity exists over the features …

Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience

PA Hart, MD Topazian, TE Witzig, JE Clain… - Gut, 2013 - gut.bmj.com
Background There is a paucity of data on long-term management of type 1 autoimmune
pancreatitis (AIP), a relapsing steroid-responsive disorder. Objective We describe our …

Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma

…, TM Habermann, JP Colgan, TE Witzig… - Journal of Clinical …, 2005 - ascopubs.org
Purpose Bleomycin pulmonary toxicity (BPT) has been well described in Hodgkin's lymphoma
(HL) patients treated with bleomycin-containing chemotherapy regimens. The influence of …

Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy

…, H Ghesquières, JP Jais, TE Witzig… - Journal of Clinical …, 2014 - ascopubs.org
Purpose Studies of diffuse large B-cell lymphoma (DLBCL) are typically evaluated by using
a time-to-event approach with relapse, re-treatment, and death commonly used as the events…

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

…, R Fonseca, JA Lust, SJ Russell, RA Kyle, TE Witzig… - Blood, 2005 - ashpublications.org
We report the results of a phase 2 trial using lenalidomide plus dexamethasone (Rev/Dex)
as initial therapy for myeloma. Thirtyfour patients were enrolled. Lenalidomide was given …

[HTML][HTML] Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma

…, R Levy, ED Jacobsen, TE Witzig… - … England Journal of …, 2017 - Mass Medical Soc
Background In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19
chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory …

Review of 1027 patients with newly diagnosed multiple myeloma

RA Kyle, MA Gertz, TE Witzig, JA Lust, MQ Lacy… - Mayo clinic …, 2003 - Elsevier
… Six years later, William Macintyre described the illness of Thomas Alexander McBean, who
had severe bone pain and at autopsy was found to have cells in the bone marrow consistent …

[HTML][HTML] Effective surgical adjuvant therapy for high-risk rectal carcinoma

…, RF Morton, MH Veeder, TE Witzig… - … England Journal of …, 1991 - Mass Medical Soc
Background Radiation therapy as an adjunct to surgery for rectal cancer has been shown to
reduce local recurrence but has not improved survival. In a previous study, combined …